Pfizer hoping to win over analysts at upcoming R&D day

Share this article:
Pfizer is slated to deliver a detailed pipeline update Thursday, as it tries to boost investor confidence in its roster of experimental compounds. The six-hour meeting will be Web cast live and is set to be hosted by new chief executive Jeffrey Kindler. He’ll have an audience of analysts ready to hear his plan for replacing erstwhile top earners such as antibiotic Zithromax and antidepressant Zoloft. Cholesterol drug Lipitor, with $12 billion in annual sales, is set to lose patent protection in 2010. Pfizer is expected to present the latest data on Lipitor’s possible successor, torcetrapib, which in large-scale clinical testing has been shown to boost good cholesterol but raise blood pressure. Earlier this month, the American Heart Association prevented Pfizer from presenting data on the closely watched developmental drug at its annual meeting after AHA officials said Pfizer broke the organization’s rules of discussing results ahead of their presentation. Pfizer said today it ended a research collaboration with Akzo's Organon unit to develop asenapine, a treatment for schizophrenia and bipolar disorder which analysts had predicted could become a blockbuster. Late-stage compounds for treating cancer and HIV are among others for which the company may provide updates.
Share this article:

Email Newsletters

More in News

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.